A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a Southwest Oncology Group study 9617
Thomas R. Chauncey(City Of Hope National Medical Center), Frederick R. Appelbaum(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), John E. Godwin(Providence Portland Medical Center), Cheryl L. Willman(Mayo Clinic), Catherine P. Leith(University of Wisconsin Carbone Cancer Center), Jeanne E. Anderson, I‐Ming Chen(University of New Mexico), Dennis F. Moore(Wichita Clinic), David R. Head(University of Southern California), Kenneth J. Kopecky(City Of Hope National Medical Center), Eric H. Kraut(The Ohio State University), Stephen H. Petersdorf(Fred Hutch Cancer Center), Matt Kalaycio(Georgetown University), Cathryn Rankin(Cleveland Clinic), Muhammad Shurafa(SWOG Cancer Research Network), Frederick W. Luthardt(University of Puget Sound)
Cited by 56
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k